CA3216783A1 - Antimicrobial and anticancer agents - Google Patents

Antimicrobial and anticancer agents

Info

Publication number
CA3216783A1
CA3216783A1 CA3216783A CA3216783A CA3216783A1 CA 3216783 A1 CA3216783 A1 CA 3216783A1 CA 3216783 A CA3216783 A CA 3216783A CA 3216783 A CA3216783 A CA 3216783A CA 3216783 A1 CA3216783 A1 CA 3216783A1
Authority
CA
Canada
Prior art keywords
cancer
compound
subject
pharmaceutical composition
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3216783A
Other languages
English (en)
French (fr)
Inventor
Thomas Mueller
Hanns Moehler
James C. Costin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geistlich Pharma AG
Original Assignee
Geistlich Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geistlich Pharma AG filed Critical Geistlich Pharma AG
Publication of CA3216783A1 publication Critical patent/CA3216783A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C07D291/06—Six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3216783A 2021-04-29 2022-04-28 Antimicrobial and anticancer agents Pending CA3216783A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163181492P 2021-04-29 2021-04-29
US63/181,492 2021-04-29
PCT/IB2022/053973 WO2022229907A1 (en) 2021-04-29 2022-04-28 Antimicrobial and anticancer agents

Publications (1)

Publication Number Publication Date
CA3216783A1 true CA3216783A1 (en) 2022-11-03

Family

ID=81598080

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3216783A Pending CA3216783A1 (en) 2021-04-29 2022-04-28 Antimicrobial and anticancer agents

Country Status (8)

Country Link
EP (1) EP4330238A1 (https=)
JP (1) JP2024515215A (https=)
KR (1) KR20240004303A (https=)
CN (1) CN117295720A (https=)
AU (1) AU2022267897A1 (https=)
CA (1) CA3216783A1 (https=)
IL (1) IL307990A (https=)
WO (1) WO2022229907A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202448502A (zh) * 2023-02-20 2024-12-16 日商大鵬藥品工業股份有限公司 Ftd・tpi調配劑、pd-1路徑拮抗劑、及vegf路徑拮抗劑之併用
WO2026074499A1 (en) * 2024-10-03 2026-04-09 Geistlich Pharma Ag Methods and compositions for inhibiting c-myc

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1160443B (de) * 1961-11-30 1964-01-02 Hoechst Ag Verfahren zur Herstellung von Tetrahydro-oxathiazin-dioxyden
GB8617482D0 (en) 1986-07-17 1986-08-28 Geistlich Soehne Ag Pharmaceutical composition
WO2013190355A1 (en) * 2012-06-18 2013-12-27 Geistlich Pharma Ag Oxathiazine derivatives as antibacterial and anticancer agents
MX392353B (es) * 2014-12-19 2025-03-24 Geistlich Pharma Ag Procedimientos para preparar compuestos de tipo oxatiazina
CA3140981A1 (en) * 2019-05-22 2020-11-26 Geistlich Pharma Ag Oxathiazin compounds for inhibiting gapdh

Also Published As

Publication number Publication date
KR20240004303A (ko) 2024-01-11
US20240199563A1 (en) 2024-06-20
EP4330238A1 (en) 2024-03-06
WO2022229907A1 (en) 2022-11-03
CN117295720A (zh) 2023-12-26
AU2022267897A1 (en) 2023-11-02
JP2024515215A (ja) 2024-04-05
IL307990A (en) 2023-12-01

Similar Documents

Publication Publication Date Title
JP7688098B2 (ja) オキサチアジン様化合物を作製する方法
EP2861573B1 (en) Oxathiazine derivatives as antibacterial and anticancer agents.
EP3188721B1 (en) Human therapeutic agents
US20260022110A1 (en) Diarylacetylene compound, preparation method thereof, and uses thereof
CA3216783A1 (en) Antimicrobial and anticancer agents
US12534443B2 (en) Processes for preparing oxathiazin-like compounds
US12612375B2 (en) Antimicrobial and anticancer agents
US12318368B2 (en) Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor
CN112716954A (zh) 氯化两面针碱的药物新用途
CN113599370B (zh) 8-oh-dpat及其衍生物在制备抗肿瘤药物中的应用
US12398128B2 (en) Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor
US12297175B2 (en) Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor
HK40076913A (en) Processes for preparing oxathiazin-like compounds
US20230063449A1 (en) Drg-mdm2-5 for use as a novel mouse double minute 2 (mdm2) inhibitor
CN120647663A (zh) 一种金刚烷修饰的喜树碱衍生物
WO2021167575A1 (en) Drg-mdm2-6 for use as a novel mouse double minute 2 (mdm2) inhibitor
WO2021162668A1 (en) Physics-driven discovery of novel small therapeutic compounds for use as a bcl-2 inhibitor
WO2021162664A1 (en) Physics-driven discovery of novel small therapeutic compounds for use as a bcl-2 inhibitor
HK1126147A (en) Derivatives of sulindac, use thereof and preparation thereof
MX2007003215A (es) Cromaderivados, medicamentos y su uso en terapias.

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250415

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250415

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260330

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260330

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260330

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260401

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260401

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260401

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260401

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260401

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260401